tirzepatide once weekly for the treatment of obesity journal club in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Effect of tirzepatide in SURMOUNT-1

Some patients maintain successfully on doses as low as 2.5-5mg per week after reaching their goal

This dual-action approach not only helps in reducing caloric intake but also aids in long-term weight management

Providers can reference these findings alongside biomarker evidence

The relative risk (RR) of all-cause dementia in subjects with baseline plasma PC DHA levels in the upper quartile compared with subjects with levels in the lower 3 quartiles was estimated after controlling for potential confounding factors

That news was related to the fact that the drug can have an impact on birth control and fertility, leading to some surprise pregnancies among women taking the medication

Its ability to suppress glucagon secretion further aids in the reduction of hepatic glucose output, thus lowering fasting and postprandial blood glucose levels